Dyslipidemia in menopause: Mechanisms and management

Obstetrical and Gynecological Survey

Volumn 61, Issue 9, 2006, Pages 608-613

  Schnatz, Peter F ^a,b   Schnatz, J David ^a,c  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

^c SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

DYSLIPIDEMIA; FAT INTAKE; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; MEDICAL RESEARCH; MENOPAUSE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIFE STYLE; MASS SCREENING; MENOPAUSE; MIDDLE AGED; RISK FACTORS;

EID: 33748299463     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000235502.95332.54     Document Type: Review

References (21)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas: American Heart Association, 2005. Available at: www.americanheart.org/downloadable/heart/1105390918119HDSStats2005Update.pdf. Accessed May 17, 2006.
2. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
4. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at: www.nhlbi.nih.gov/guidelines/ cholesterol/profmats.htm. Accessed May 17, 2006.
5. Grundy SM, Cleeman JI, Merz NB, et al.; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
6. Kim C, Hofer TP, Kerr EA. Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. J Gen Intern Med 2003;18:854-863.
7. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-1307.
8. Jha AK, Varosy PD, Kanaya AM, et al. Black and white women with heart disease. Circulation 2003;108:1089-1094.
9. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-452.
10. Mobasseri S, Liebson PR, Klein LW. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective. Cardiol Rev 2004;12:287-298.
11. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Ann Intern Med 1997;157:2413-2446.
12. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
13. Miller M. Is hypertriglyceridemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J 1998;19(suppl H):H18-H22.
14. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (HERS). JAMA 1998;280:605-613.
15. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
16. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199-208.
17. Speroff L. Postmenopausal hormone therapy and cardiovascular disease: one view of the elephant. The Journal of The North American Menopause Society 2005;12:357-358.
18. Karwacki-Marugg CL, Schnatz JD. Consultation and management of patients with lipid disorders: importance of life-style changes and intensive follow-up. Conn Med 2006;70:133-139.
19. Neal RC, Jones PH. Lipid-lowering: can ezetimibe help close the treatment gap? Cleve Clin J Med 2003;70:777-783.
20. Brown B, Zhao X, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592.
21. Schnatz PF. The women's life center: menopause clinics help provide quality care and education. Menopause Management 2004;13:18-32.